Publications
Detailed Information
Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Gadgeel, Shirish | - |
dc.contributor.author | Shaw, Alice T. | - |
dc.contributor.author | Barlesi, Fabrice | - |
dc.contributor.author | Crino, Lucio | - |
dc.contributor.author | Yang, James Chih-Hsin | - |
dc.contributor.author | Dingemans, Anne-Marie C. | - |
dc.contributor.author | Kim, Dong-Wan | - |
dc.contributor.author | de Marinis, Filippo | - |
dc.contributor.author | Schulz, Mathias | - |
dc.contributor.author | Liu, Shiyao | - |
dc.contributor.author | Gupta, Ravindra | - |
dc.contributor.author | Kotb, Ahmed | - |
dc.contributor.author | Ou, Sai-Hong Ignatius | - |
dc.date.accessioned | 2020-04-27T11:05:10Z | - |
dc.date.available | 2020-04-27T11:05:10Z | - |
dc.date.created | 2019-03-19 | - |
dc.date.issued | 2018-01 | - |
dc.identifier.citation | British Journal of Cancer, Vol.118 No.1, pp.38-42 | - |
dc.identifier.issn | 0007-0920 | - |
dc.identifier.other | 72783 | - |
dc.identifier.uri | https://hdl.handle.net/10371/165242 | - |
dc.description.abstract | Background: We evaluated the cumulative incidence rate (CIR) of central nervous system (CNS) and non-CNS progression in alectinib-treated patients with anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) to determine the extent to which alectinib may treat or control CNS disease. Methods: Patients with crizotinib-pretreated locally advanced or metastatic disease received alectinib 600 mg orally twice daily in two phase II trials. All patients underwent baseline imaging and regular centrally reviewed scans. Results: At 24 months, the CIR for CNS progression was lower in patients without vs with baseline CNS metastases (8.0 vs 43.9%). Patients with baseline CNS disease and prior radiotherapy had a higher CIR of CNS progression than radiotherapy-naive patients (50.5 vs 27.4%) and a lower CIR of non-CNS progression (25.8 vs 42.5%). Adverse events leading to withdrawal occurred in 5.9% and 6.7% of patients with and without baseline CNS metastases, respectively. Conclusions: This analysis indicates a potential role for alectinib in controlling and preventing CNS metastases. | - |
dc.language | 영어 | - |
dc.publisher | Nature Publishing Group | - |
dc.title | Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC | - |
dc.type | Article | - |
dc.contributor.AlternativeAuthor | 김동완 | - |
dc.identifier.doi | 10.1038/bjc.2017.395 | - |
dc.citation.journaltitle | British Journal of Cancer | - |
dc.identifier.wosid | 000419758900007 | - |
dc.identifier.scopusid | 2-s2.0-85040316540 | - |
dc.citation.endpage | 42 | - |
dc.citation.number | 1 | - |
dc.citation.startpage | 38 | - |
dc.citation.volume | 118 | - |
dc.identifier.sci | 000419758900007 | - |
dc.description.isOpenAccess | Y | - |
dc.contributor.affiliatedAuthor | Kim, Dong-Wan | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | CELL LUNG-CANCER | - |
dc.subject.keywordPlus | OPEN-LABEL | - |
dc.subject.keywordPlus | CRIZOTINIB | - |
dc.subject.keywordAuthor | alectinib | - |
dc.subject.keywordAuthor | ALK positive | - |
dc.subject.keywordAuthor | central nervous system | - |
dc.subject.keywordAuthor | cumulative incidence rates | - |
dc.subject.keywordAuthor | disease progression | - |
dc.subject.keywordAuthor | non-small-cell lung cancer | - |
dc.subject.keywordAuthor | phase II | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.